Abbott Laboratories Stock News

ABT vs. RMD: Which Stock Is the Better Value Option?

Here is how Abbott (ABT) and Organogenesis (ORGO) have performed compared to their sector so far this year.

ABBOTT PARK, Ill., Dec. 21, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) will present virtually at the 40th Annual J.P.

Bad news related to COVID-19 could be good news for these stocks.

Total income will finish 2021 at $13,662, an increase of 13.9% over the previous year.

First Long Island Investors LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 2.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 378,529 shares of the healthcare product makers stock after purchasing an additional 8,601 shares during the period. Abbott []

Busey Wealth Management raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 219.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,056 shares of the healthcare product makers stock after purchasing an additional 66,000 shares during the quarter. Busey Wealth Managements []

Intrua Financial LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 32.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,762 shares of the healthcare product makers stock after buying an additional 677 shares during the period. Intrua Financial LLCs holdings in Abbott Laboratories []

Abbott Laboratories (NYSE:ABT) EVP Andrea F. Wainer sold 14,500 shares of the businesss stock in a transaction on Monday, December 13th. The stock was sold at an average price of $135.00, for a total value of $1,957,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through []

The Heart Pump Device Market research report provides broad, subjective bits of knowledge on the potential and specialty portions or regions displaying good growth. The Heart Pump Device Market research report comprehensively investigates the current and developing business sector patterns

This Infertility Testing And Treatment market report analyzed the market conditions of key region of the world including product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. The report introduced the new project SWOT analysis,

Carderock Capital Management Inc. grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 60,390 shares of the healthcare product makers stock after acquiring an additional 423 shares during the quarter. Abbott Laboratories accounts for []

Hudson Value Partners LLC reduced its holdings in Abbott Laboratories (NYSE:ABT) by 1.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,529 shares of the healthcare product makers stock after selling 135 shares during the quarter. Hudson Value Partners LLCs holdings []

Abbott Laboratories (NYSE: ABT ) traded at a new 12-month high today of $139.11. Approximately 4 million shares have changed hands today, as compared to an average 30-day volume of 5.4 million shares. In the past 12 months, Abbott Laboratories'' share prices are bracketed by a low of $105.36 and a high of $139.11 and are now at $138.57, 32% above that low price. Abbott Laboratories defies analysts with a current price ($138.57) 39.0% above its average consensus price target of $84.50. Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant … Full story available on Benzinga.com

Pinnacle Wealth Planning Services Inc. increased its position in Abbott Laboratories (NYSE:ABT) by 5.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 10,500 shares of the healthcare product makers stock after buying an additional 556 shares during the quarter. Pinnacle Wealth Planning Services Inc.s holdings in Abbott Laboratories were worth $1,240,000 as of []